Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Acute Pancreatitis I: Introduction

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.

Gut microbes·2026

Same author

Rapid Onset of Iron Overload Cardiomyopathy in Cirrhosis.

JACC. Case reports·2026

Same author

Frailty Increases Hospitalization Rates in an Ambulatory Cohort of Patients With Cirrhosis: The North American Consortium for the Study of End-Stage Liver Disease 3 Prospective Cohort.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Variceal hemorrhage in cirrhosis.

Expert review of gastroenterology & hepatology·2026

Same author

The management of hepatorenal syndrome-acute kidney injury (HRS-AKI): A national survey of hepatology provider practices.

Hepatology communications·2026

Search research articles

Related Experiment Video

Updated: May 20, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Acute-on chronic liver failure.

Rajiv Jalan¹, Pere Gines, Jody C Olson

¹Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, United Kingdom. r.jalan@ucl.ac.uk

Journal of Hepatology

|July 4, 2012

Summary

This summary is machine-generated.

Acute-on-chronic liver failure (ACLF) is a severe condition where liver function rapidly declines in cirrhosis patients, often leading to organ failure and high mortality. This review explores ACLF

More Related Videos

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl₄) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Related Experiment Videos

Last Updated: May 20, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl₄) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Area of Science:

Hepatology and Gastroenterology
Critical Care Medicine
Immunology

Background:

Acute-on-chronic liver failure (ACLF) is a distinct clinical syndrome characterized by acute decompensation of pre-existing liver disease.
It involves rapid deterioration of liver function, organ failure, and high short-term mortality in patients with cirrhosis.
While recognized clinically, prospective data defining ACLF is limited, and its pathophysiology is complex.

Purpose of the Study:

To review the current understanding of acute-on-chronic liver failure (ACLF).
To discuss the clinical presentation, prognostic factors, and pathophysiological mechanisms of ACLF.
To identify potential biomarkers and therapeutic targets for ACLF intervention.

Main Methods:

This is a review article, synthesizing existing literature on ACLF.
It focuses on clinical, prognostic, and pathophysiological aspects.
Potential biomarkers and therapeutic strategies are discussed based on current evidence.

Main Results:

ACLF is characterized by acute liver dysfunction superimposed on chronic liver disease, often triggered by specific events.
Altered host responses to injury and infection are critical in ACLF development.
The review highlights the need for further research into definitive diagnostic criteria and effective treatments.

Conclusions:

Acute-on-chronic liver failure (ACLF) represents a severe clinical entity with significant mortality.
Understanding the complex pathophysiology, including host response and infection, is crucial.
Further research is needed to identify reliable biomarkers and develop targeted therapies for ACLF.